Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Madalena Tarsounas' group have recently published two new papers in EMBO Molecular Medicine and Nature Communications.

The Tarsounas group, Department of Oncology

In Tacconi et al . they discovered that chlorambucil, an alkylating agent in clinical use for the treatment of leukemia, has a high therapeutic potential against BRCA1/2-mutated tumours. Importantly, while being equally effective as cisplatin against this tumour subset, chlorambucil showed significantly lower overall toxicity.

Find the original publication here:

https://www.embopress.org/lookup/doi/10.15252/emmm.201809982

 

In Reisländer et al. they demonstrated that loss of BRCA2 leads to activation of the cGAS-STING pathway which results in a cell-intrinsic type I interferon response. Importantly, this innate immune response in BRCA2-deficient cells is potentiated by treatment with PARP inhibitors.

Find the original publication here:

https://www.nature.com/articles/s41467-019-11048-5

 

Similar stories

Lung abnormalities found in long COVID patients with breathlessness

Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.

Eileen Parkes secures Clinical Research Career Development Fellowship

Eileen is awarded funding for her research into the tumour microenvironment

MP Anneliese Dodds tours Oxford cancer research

Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.